NEW YORK--(BUSINESS WIRE)--IRX Therapeutics, Inc. (IRX) today announced the appointment of Luba Greenwood, Vice President of Global Business Development and Mergers & Acquisitions at F. Hoffmann-La Roche, Diagnostics, to its Board of Directors.
Luba Greenwood brings to IRX a wealth of pharmaceutical and biotechnology industry experience, expertise in building innovative technology companies and providing strategic counsel to global corporations. Her career has spanned leadership roles in venture investing, business development, mergers & acquisitions, law, consulting and operations. Luba recently served as Venture Partner at Colt Ventures, and led business development and strategy for Pronutria, a Flagship VenturesLabs company. Prior to that, Luba served as Senior Mergers & Acquisitions Counsel at Pfizer Inc.
“Luba is a proven and respected leader in the life sciences sector,” said Mark Leuchtenberger, President and Chief Executive Officer of IRX Therapeutics. “She has excelled as an investor, business development professional, lawyer and corporate strategist. We are honored to have Luba join our Board of Directors and look forward to her contributions as we advance the clinical development of IRX-2 in head and neck cancer and other indications.”
“I am thrilled to join IRX Therapeutics’ Board of Directors as the company advances IRX-2, a novel primary cell-derived biologic, into multiple clinical trials in oncology,” said Luba Greenwood. “I look forward to working with the management team as they explore the potential to reduce immune suppression in the tumor microenvironment with IRX-2. The encouraging clinical results reported to date suggest that IRX-2 has the potential to improve outcomes in a variety of cancer indications.”
Luba is an adjunct professor at Boston University School of Management where she teaches business law, and Boston University Law School where she teaches a course on life sciences. Luba has served on the board of the Longwood Symphony Orchestra, is a co-chair of MassBio’s Entrepreneur’s University, mentor for the MIT 100K Entrepreneurship Competition and a judge for MassChallenge and the Young Entrepreneurs Initiative. In 2014, she received the Science Club for Girls Catalyst Award for her commitment to fostering women talent and advocating for women in science and technology. Luba received a J.D. from Northeastern University and a B.A. from Brandeis University.
About IRX Therapeutics and IRX-2
IRX Therapeutics is a clinical-stage company developing novel immunotherapies focused on reducing the immune suppression that is seen in the cancer tumor micro-environment, restoring immune function, and activating a coordinated immune response against the tumor.
The lead candidate, IRX-2, is a proprietary therapeutic containing numerous active cytokine components, which data suggests may restore and activate multiple immune cell types, including T cells, dendritic cells, and natural killer cells, that are known to recognize and attack tumors. IRX-2 is a primary cell-derived biologic of produced by stimulation of human peripheral blood mononuclear cells (PBMCs) obtained from heathy donor whole blood. Data collected to date suggest that IRX-2 reduces the immune suppression that is often seen in the cancer tumor microenvironment. This immunomodulatory activity appears to occur through the restoration of immune function and activation of a coordinated immune response against the tumor.
Currently, IRX-2 is being studied in an ongoing Phase 2b clinical trial in patients with newly diagnosed Stage II, III, and IVA squamous cell carcinoma of the head and neck (SCCHN) (INSPIRE) http://inspirehnc.com/ (clinicaltrials.gov NCT02609386) as well as in investigator-sponsored trials in pre-operative early stage breast cancer (ESBC) (clinicaltrials.gov NCT02950259).and in cervical squamous intraepithelial neoplasia 3 (CIN3) or squamous vulvar intraepithelial neoplasia 3 (VIN3) (clinicaltrials.gov NCT03267680).
For more information about the Company and its clinical programs, please visit www.IRXTherapeutics.com.
